United Therapeutics Corp. (NASDAQ:UTHR)‘s stock had its “buy” rating reaffirmed by research analysts at Cowen and Company in a research report issued to clients and investors on Friday. They presently have a $144.00 price target on the biotechnology company’s stock. Cowen and Company’s price target indicates a potential upside of 13.38% from the company’s previous close.

A number of other research analysts have also recently commented on UTHR. Argus reiterated a “hold” rating on shares of United Therapeutics Corp. in a research note on Tuesday, August 23rd. Zacks Investment Research cut United Therapeutics Corp. from a “buy” rating to a “hold” rating in a research note on Monday, August 1st. JPMorgan Chase & Co. dropped their price target on United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating for the company in a research note on Friday, July 29th. Jefferies Group reiterated a “hold” rating and issued a $120.00 price target on shares of United Therapeutics Corp. in a research note on Friday, July 29th. Finally, HC Wainwright reiterated a “hold” rating on shares of United Therapeutics Corp. in a research note on Friday, July 29th. Nine investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $136.09.

Analyst Recommendations for United Therapeutics Corp. (NASDAQ:UTHR)

United Therapeutics Corp. (NASDAQ:UTHR) opened at 127.01 on Friday. United Therapeutics Corp. has a 12-month low of $97.52 and a 12-month high of $164.04. The company has a market capitalization of $5.52 billion, a price-to-earnings ratio of 6.14 and a beta of 1.46. The firm’s 50-day moving average price is $124.24 and its 200 day moving average price is $116.14.

United Therapeutics Corp. (NASDAQ:UTHR) last released its earnings results on Thursday, July 28th. The biotechnology company reported $4.55 earnings per share for the quarter, topping the consensus estimate of $3.22 by $1.33. United Therapeutics Corp. had a return on equity of 49.30% and a net margin of 64.26%. The firm earned $412.60 million during the quarter, compared to analysts’ expectations of $395.15 million. During the same period in the prior year, the company earned $2.55 earnings per share. The company’s quarterly revenue was up 18.8% on a year-over-year basis. On average, analysts expect that United Therapeutics Corp. will post $15.82 earnings per share for the current year.

In other news, Director Christopher Patusky sold 5,000 shares of the stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $122.73, for a total transaction of $613,650.00. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at approximately $613,650. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,293 shares of the stock in a transaction dated Thursday, July 7th. The stock was sold at an average price of $109.87, for a total transaction of $142,061.91. Following the transaction, the chief executive officer now directly owns 1,433 shares in the company, valued at approximately $157,443.71. The disclosure for this sale can be found here. Company insiders own 7.50% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Scopia Capital Management LP boosted its position in United Therapeutics Corp. by 48.1% in the first quarter. Scopia Capital Management LP now owns 4,219,281 shares of the biotechnology company’s stock worth $470,154,000 after buying an additional 1,370,698 shares during the period. Geode Capital Management LLC boosted its position in United Therapeutics Corp. by 21.1% in the first quarter. Geode Capital Management LLC now owns 455,719 shares of the biotechnology company’s stock worth $50,761,000 after buying an additional 79,502 shares during the period. UBS Asset Management Americas Inc. boosted its position in United Therapeutics Corp. by 7.3% in the first quarter. UBS Asset Management Americas Inc. now owns 226,285 shares of the biotechnology company’s stock worth $25,215,000 after buying an additional 15,402 shares during the period. Nuveen Asset Management LLC boosted its position in United Therapeutics Corp. by 10.2% in the first quarter. Nuveen Asset Management LLC now owns 65,047 shares of the biotechnology company’s stock worth $7,248,000 after buying an additional 6,014 shares during the period. Finally, Norges Bank bought a new position in United Therapeutics Corp. during the fourth quarter worth about $65,955,000.

About United Therapeutics Corp.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.